Endosense Overview

  • Founded
  • 2003


  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $320M

Endosense General Information


Developer of technology for contact-force measurement in catheter ablation. The company focuses on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias. The company pioneered the use of contact force measurement in catheter ablation with the development of the TactiCath, the industry's first force-sensing ablation catheter.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Surgical Devices
Primary Office
  • Chemin du Grand-Puits 42
  • 1217 Meyrin
  • Switzerland
+41 022 000 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Endosense Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 19-Aug-2013 $320M 00000 00000 Completed Generating Revenue
3. Later Stage VC (Series C) 05-Mar-2013 000.00 00000 Completed Generating Revenue
2. Later Stage VC (Series B) 01-Sep-2009 $36M $56M Completed Generating Revenue
1. Early Stage VC (Series A) 21-Nov-2005 $20M $20M Completed Product Development
To view Endosense’s complete valuation and funding history, request access »

Endosense Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
3i Group PE/Buyout Minority 000 0000 000000 0
Andera Partners PE/Buyout Minority 000 0000 000000 0
DEFI Gestion PE/Buyout Minority 000 0000 000000 0
Gimv PE/Buyout Minority 000 0000 000000 0
NGN Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »